Fibroscan® and Shear Wave correlated well in hepatic fibrosis evaluation of patients with chronic liver diseases “in real life situation”

Honorable Tegwendé Zougmoré, MDa,b, Jean François David Cadranel, MD, Professor CMHPa,*
Gildas Fantognon, MDa, Badia Azzi, MDd, Ryad Smadhi, MDa, Jean René Ngele Efoulé, MDa, Samir Mrabti, MDa,
Ratmony Heng, MDb, Marie Adrienne Ntsama, MDa, Mourad Medmoun, MDa, Firoozeh Kazeroni, MDb, 
Tristan Le Magoarou, MDa

Abstract

Background: A new noninvasive medical device based on ultrasound elastography such as the Shear Wave Elastography (SWE) was designed in order to measure the liver hardness. The purpose of this work was to evaluate the correlation of the results of the liver elasticity measurements obtained by Fibroscan® (FS) and SWE for patients with chronic liver diseases.

Methods: Between January and October 2017, the patients who were followed during this period of time underwent noninvasive assessments of liver fibrosis by SWE in the intercostal spaces during abdominal ultrasound procedures and/or FS. The correlation between FS and SWE was estimated and tested at a 0.05 significance level.

Results: Four hundred and seventy-six patients were included in this study. The main etiologies of chronic liver disease were non-alcoholic fatty disease (NAFLD), chronic viral hepatitis B (HBV) and chronic viral hepatitis C (HCV). All patients underwent a SWE and 167 among them underwent a FS procedure. The patients who were followed revealed a median FS measurement of 5.80 kpa (Q25 = 4.90 kPa; Q75 = 8 kPa) and a median SWE measurement of 7.00 kPa (Q25 = 6.10 kPa; Q75 = 8.10 kPa). We could observe a significant correlation between the FS and SWE measurements (0.49; P = .001) in the total cohort. The average absolute difference between the measurements of these 2 methods was of 2.54 kPa (sd = 3.39). There was no significant correlation for patients with NAFLD no matter whether they presented with signs of suspected non-alcoholic steatohepatitis (NASH) or not (R = 0.20; P = .108). All patients intending to perform the examination were able to undergo the SWE, allowing 33.3% of the patients who failed the FS to have a noninvasive evaluation of their fibrosis.

Conclusion: The SWE technique proved to be as efficient as the FS one for the evaluation of the liver fibrosis in real life situation.

Abbreviations: 2D-SWE = two-dimensional Shear Wave elastography, ALAT = alanine aminotransferase, AP = alkaline phosphatases, ASAT = aspartate aminotransferase, AUROC = area under the receiver operating characteristic curve, BMI = body mass index, FS = fibroscan®, GGT = gamma-glutamyl transpeptidase, GHPSO = groupe hospitalier public du sud de l’oise, HBV = hepatitis B, HCV = hepatitis C, IQR = interquartile range, kPa = kilopascals, LSM = liver stiffness measurement, NAFLD = non alcoholic fatty disease, NASH = non alcoholic steatohepatitis, ROI = region of interest, SWE = shear wave elastography, TE = transient elastography.

Keywords: chronic liver diseases, elastography Shear Wave®, Fibroscan®, real life

1. Introduction

The chronic liver disease is a major public health problem with an estimated 1.5 million deaths per year worldwide due to a cirrhosis and its complications.[1] Indeed, chronic inflammation of the liver, whatever the cause, can lead to the formation of fibrosis, the ultimate stage of which is cirrhosis. Cirrhosis, a true precancerous state, provides the basis for hepatocellular carcinoma, even though it may occur in a noncirrhotic liver. Therefore, an accurate assessment of the degree of hepatic fibrosis is essential for a long-term follow-up and a treatment when there is a chronic liver disease.[2] The liver biopsy remains the gold standard for in order to evaluate a liver fibrosis.[3] It has largely been replaced because of its invasiveness by non-invasive evaluations of the liver fibrosis, first

The authors have no funding and conflicts of interest to disclose.

Data sharing not applicable to this article, as no datasets were generated or analyzed during the current study.

Supplemental Digital Content is available for this article.

*Correspondence: Jean François David Cadranel, Department of Hepatology and Gastroenterology, GHPSO, Creil, France (e-mail: jfrancois.cadranel@ch-creil.fr).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

http://dx.doi.org/10.1097/MD.0000000000030025
for patients suffering from chronic hepatitis C (HCV). Several composite biological scores have been developed, the most widely used of which is Fibrotest®.[14] Then, the impulse elastometry or Fibroscan® (FS) was developed. This technique allows an evaluation of the liver elasticity through a mechanical vibration. The development of an XL probe has made it possible to reduce the failure rate for obese patients, but this technique remains limited in cases where there is ascites. Thus, in order to overcome this shortcoming, the Shear Wave Elastography (SWE) which is also known as supersonic or 2-dimensional (2D) shear imaging, was developed by the Aixplorer unit.[15] The SWE has the advantage of providing images of the liver stiffness in real time because the shear waves are generated by ultrasound pushes. The SWE is providing a real time quantitative map of the liver stiffness.[6–8] The aim of our study was to analyse the correlation of liver stiffness measurements (LSM) through FS and SWE procedures in real life situations where a large population of patients with chronic liver diseases trigger by different causes was followed in a non academic hospital in real life situations.

2. Patients and Methods

2.1. Patients

Our prospective study lasted 10 months. From January to October 2017, 476 consecutive patients followed in the Hepatology and Gastroenterology department were included in the study after giving their consent to take part in it and if they met the following criteria: 1) at least be 18 years old; 2) presenting with chronic liver disease due to various causes; 3) underwent SWE and/or FS. For each patient, the following demographic and clinico-biological data were reported: the age, gender, cause of liver diseases, body mass index (BMI), existence or not of cirrhosis, prothrombin time, transaminases, alkaline phosphatases (AP) and gamma-glutamyl transpeptidase activities (GGT) the platelet count and the total bilirubin concentration. In contrast, the patients with an obvious cirrhosis, decompensated cirrhosis, prothrombin time, transaminases, alkaline phosphatases and clinico-biological data were reported: the age, gender, cause of liver diseases, body mass index (BMI), existence or not of cirrhosis, acute liver disease and the ones who refused to take part in the study were excluded.

3. Methods

3.1. Liver stiffness measurement

The SWE and FS tests were performed after at least 6 hours of fasting with a less-than 6 months interval between the 2 examinations. A Transient Elastography (TE) was performed by a FS 502 Touch model (Echosens, Paris, France) according to the previously described methods.[9] The examinations were performed by 3 board certified hepatologists using the M probe. The TE was performed in the right lobe of the liver through an approach from the right anterior axillary line. The measurements were performed under gentle breath-holds without deep inspirations. Almost all the 5 examinations were performed by an experienced radiologist, previously trained in the use of the Shear Wave technique. A SWE measurement was considered valid if the IQR was estimated to be <30% of the median value. A technical failure was defined as the inability to obtain at least 3 valid measurements.[14]

4. Operational definitions

A chronic liver disease was defined by persistent liver test abnormalities associated with an identified cause (alcohol, virus...) for at least six months.

A significant fibrosis corresponded to F ≥ 2 fibrosis. The threshold values of 7.7 kPa and 13 kPa had been retained at the FS to define a significant fibrosis and cirrhosis respectively in the absence of sufficient liver biopsy data which is the “gold standard”.[13]

5. Ethical considerations

All patients gave their consent to participate in the study. The examinations were performed blinded to the outcome of other examinations. These examinations were performed as parts of the patients’ usual care. The protocol was in accordance with the Helsinki Declaration and approved by the ethics committee of groupe hospitalier public du sud de l’oise (GHPSO).

6. Data analysis

A data analysis was performed with the R software and the R Studio interface.[16] Some differences between quantitative variables were estimated with Student t-test with Welch correlation at the 0.05 significance level. The Bland Altman analysis was used to assess the degree of agreement between the 2 methods (SWE and FS) with a 95% confidence interval.

7. Results

7.1. Characteristic of patients

During the study period, 834 patients had consulted in the hospital in the hepatology and gastroenterology Department as outpatients and 476 patients with chronic liver diseases were included (Fig. 1). All patients gave their consent to participate in the study. The average age of the patients was 60 years and 56% of patients were men. The demographic, clinical and laboratory parameters of 476 patients in this study was summarised in Table 1.

7.2. Liver stiffness measurements and their correlation

A SWE was performed on all patients. The median LSM by 2D-SWE was of 7.00 kPa (Q25 = 6.10 kPa; Q75 = 8.10 kPa). This median LSM was of 7.1 kPa and of 13.3 kPa in cirrhotic and noncirrhotic patients respectively (P = .0085).

A FS was performed on 167 patients. The median LSM by FS was of 5.80 kPa (Q25 = 4.90 kPa; Q75 = 8 kPa.). A FS had been performed in patients with viral hepatitis B (HBV), HCV and NAFLD respectively in 52.1%, 37.4% and 26.6% of the cases.

The LSM by TE with M probe was not technically feasible for 78 (33.3%) NAFLD patients. In the total patient cohort, the correlation of LSM between TE and SWE (Fig. 2) showed a significant association (R = 0.47; P < .001).

In addition, Bland and Altman analysis showed a degree of agreement or concordance of the results (95% of liver elasticity values were within ± 2 standard deviations of the average difference) between the 2 methods SWE and FS with a 95% confidence interval. This method of analysis is reported in Figure 3.
limitations, first in chronic HCV and then in other diseases.[3] This costly invasive procedure with rare but sometimes severe complications is difficult to repeat in order to regularly follow the evolution of fibrosis in patients.[17,14] Moreover, the histological analysis is not the best option due to its high inter- and intraoperator variability and sampling fluctuations inherent to its technique. Given all these limitations, a few reliable and reproducible noninvasive tests especially the LSM by elastography have been developed to assess a liver fibrosis. The diagnostic performance of the FS has been compared in the literature to the liver biopsy. Several studies reported an excellent diagnostic performance of the TE for the detection of advanced fibrosis and cirrhosis in chronic HCV infection, with areas under the receiver operating characteristic curve (AUROCs) of 0.88–0.99.[9,19,20] Some similar results were subsequently reported by other studies in chronic HCV and HBV infections.[21–28]

Several meta analyses have confirmed the excellent diagnostic accuracy of the TE for diagnosing cirrhosis (AUROC, 0.93–0.96), even better for detecting moderate fibrosis (F2–F4) (AUROC, 0.83–0.88), with cutoffs ranging from 7.0–7.9 kPa for the diagnosis of moderate fibrosis (F2–F4) and 11.3–15.6 kPa for the diagnosis of cirrhosis (F4).[17,21–23] A meta-analysis of the TE performance using the M probe in NAFLD (n = 854) reported a pooled sensitivity and specificity of 79% and 75% for F2–F4, 85% and 82% for F3–F4, and 92% and 92% for stage F4.[22] The pooled AUROC was not reported, though AUROC ranges for the included studies were 0.79–0.87 for F2–F4, 0.76–0.98 for F3–F4, and 0.91–0.99 for stage F4. The introduction of the XL probe has led to more reliable results than with the M probe in the cases of overweight or obese patients.[34]

In our ‘real life situation study’ we found a fairly good correlation between the liver stiffness measurement performed with FS and share wave techniques. One limitation of our study relies on the fact that we were not equipped with the “XL” probe which contrasted with a population presenting a chronic hepatopathy due to NAFLD with or without NASH in 50% of the cases. The factors associated with stiffness measurement failures by FS in our study could be explained by a high BMI (average BMI at 31.42 kg/m²), and the unavailability of the “XL” probe which was recently developed and dedicated to overweight patients. Our results were superior to those reported by Foucher et al who had a 5% measurement failure rate and 15% of cases of noninterpretable results, with obesity as the main limiting factor.[34]

All patients intending to perform the examination were able to undergo a SWE elastography, allowing 33.3% of patients with a failed FS to have a noninvasive evaluation of fibrosis in our study.

The average SWE values in noncirrhotic and cirrhotic patients were 7.1 kPa and 13.3 kPa, respectively (P = .0085). These results corroborate those of the meta-analysis by Hermann et al who found an optimal threshold of 13.5 kPa for the diagnosis of cirrhosis.[35] The results obtained confirm that SWE allowed the diagnosis of cirrhosis and, therefore, the identification of patients who should be monitored for the development of different complications and treated.

In our study, the use of the SWE method for the elasticity assessment was compared to the FS validated for this purpose. The use of the SWE method offers the advantage of being integrated into a conventional ultrasound system. It can be performed during a standard B-mode liver ultrasound, which is commonly used for the follow-ups of patients suffering from a chronic liver disease. In addition, the advantages offered by the SWE include the ability to choose the positioning of the ROI in the liver, thus avoiding interfering structures such as large blood masses.

### 7.3. Liver stiffness measurements in relationship with the cause of chronic disease

The median LSM by 2D-SWE and TE was respectively 6.1 ± 1.3 and 5.9 ± 2.2 for patients with chronic HBV; 7.8 ± 3 and 10.9 ± 12.9 in patients with chronic HCV; 7.6 ± 2.6 and 7 ± 4.2 for patients with NAFLD. There was a significant correlation of LSM by TE and 2D-SWE for patients with chronic HBV (R = 0.49; P < .001; Fig. 4) and chronic HCV (R = 0.50; P < .001; Fig. 5).

However, there was no significant correlation for patients with NAFLD no matter whether they presented with signs of suspected NASH or not (R = 0.20; P = .108; Fig. 6).

### 8. Discussion

The Liver biopsy remains the gold standard for the evaluation of the liver fibrosis. It has been replaced because of its numerous

---

### Table 1

Characteristics of included patients and etiologies of liver disease.

| Characteristic                  | Value               |
|--------------------------------|---------------------|
| **Men**                        | 276 (56.1%)         |
| Mean age                       | 60 ± 13.8           |
| Cirrhotic patients             | 43 (9%)             |
| Body mass index (kg/m2)        | 31.42 (26–42.3)     |
| Median prothrombin time (%)    | 93.9 (32–142)       |
| Median platelets (G/L)         | 221 (27–929)        |
| Median AST                     | 32.1 (5–158)        |
| Median ALT                     | 33.5 (5–185)        |
| Median total bilirubin (µM/L)  | 9.9 (2.5–66)        |
| Median glutamyl transpeptidase (IU/L) | 56.9 (5.2–644) |
| Median Alkaline phosphatase (IU/L) | 73.3 (8.1–249) |
| NAFLD                          | 235 (49.4%)         |
| Chronic hepatitis B            | 94 (19.7%)          |
| Chronic hepatitis C            | 91 (19.1%)          |

ASAT = aspartate aminotransferase, ALAT = alanine aminotransferase, NAFLD = non alcoholic fatty liver disease.
vessels and bile ducts. In addition, the SWE method is not influenced by obesity or ascites.

Our study, conducted in real life situations, showing patients suffering from a chronic liver disease and consecutively followed up in medical consultation, allowed us to evaluate the correlation of the elasticity measurements obtained between the FS and the SWE methods on the one hand and the level of agreement between these 2 methods on the other hand.

A significant linear correlation ($R = 0.47; P < .001$) was observed between the LSM obtained by FS and SWE techniques regardless of the cause of the liver disease.

This Pearson correlation had been strengthened in our study by Blant Altman analysis, which enhanced the concordance between the FS and SWE methods. Therefore, the SWE in the light of the data in the literature constitutes a new physical method tool for the evaluation of the fibrosis.[35,36]

In the subgroup of HBV-infected patients, there was a significant correlation ($R = 0.486; P < .001$), as well as in the subgroup of HCV-infected patients ($R = 0.501; P = .003$).

These “real life situation” results confirmed the data of the literature.[35,36]

More recent studies have evaluated the SWE method in patients with a chronic HBV infection and found diagnostic accuracies at AUROC levels of 88–92%, 93–95% and 95–98% for the diagnosis of significant fibrosis, severe fibrosis and cirrhosis respectively.[37,38] In the meta-analysis by Hermannet al.,
the AUROCs were 91%, 93%, and 96% for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis, respectively.\[35\]

In addition, the SWE method was better than the FS one for the diagnosis of all stages of the fibrosis and significantly better for the diagnosis of significant fibrosis and cirrhosis \( (P < .001 \) and \( P = .007 \), respectively).\[35\]

Zeng et al also showed that the diagnostic performance of the SWE method was significantly better than the FS one.\[38\]

One explanation could be the increased ROI of the SWE method which allows the examination of a larger area of the liver than the FS method.\[38\]

In a study of 121 HCV patients comparing the SWE method to the FS one with histology as the reference method, an excellent diagnostic accuracy of the SWE was found for all stages of fibrosis (AUROC: 92%, 98% and 98% for the diagnosis of significant fibrosis, severe fibrosis and cirrhosis). This diagnostic performance of the SWE was significantly superior to the one of the FS.\[8\] This corroborates quite well the results of Hermann et al with AUROCs of 86%, 92% and 93% for the diagnosis of significant fibrosis, severe fibrosis and cirrhosis respectively.\[35\]

The AUROC of 0.022–0.084 (95% confidence interval) of the SWE was greater than the AUROC of the FS for diagnosing a significant fibrosis \( (P = .001) \) and 0.003–0.034 for diagnosing a cirrhosis \( (P = .022) \) for the whole patients in the meta-analysis by Hermann et al.\[35\]

This difference was more significant for patients suffering from HBV. The optimal thresholds were 7.1, 9.2, and 13.5 kPa, respectively. When comparing the SWE to elastography in this
meta-analysis, no significant difference was found between the 2
methods if the FS quality criteria were met. The SWE has the
advantage of being simple to use, and with a good clinical
application. The SWE proved to be less expensive (<15,000 euros) than
the FS and could be a good alternative for assessing the liver
elasticity in developing countries with a very high HBV endemicity.

In the subpopulation of patients with NAFLD with or without
NASH, our study did not find a significant correlation
between the SWE and FS methods ($R = 0.20; P = .108$). This
could be explained on the one hand by the small number of
patients who benefited from a FS in this subpopulation (26.6%),
and on the other hand by hepatic steatosis and hepatic inflam-
ination in NAFLD patients with NASH which would influence
the result in the direction of an increase in the liver hardness.
For de Ledinghen et al, several factors other than a fibrosis influ-
ence the result of the FS in the sense of an increase in the liver
hardness which favours false positive results: hepatic inflam-
ination, steatosis, cholestasis, heart failure, postprandial condi-
tion. These factors must therefore be taken into account when
interpreting the results. For Olteanu et al, the BMI, the level
of necrotic-inflammatory activity and hepatic steatosis, signifi-
antly influence the correlation between the FS and SWE values
($p$ respectively at 0.0020; 0.001; 0.004). Conversely, Herman et al reported a good significant correlation
with the FS and SWE values in the assessment of a liver
fibrosis in NAFLD patients.

Our study has several limitations. The “real life” data were
generated during routine patient care.

First, it was not possible to assess the liver elasticity through
FS and SWE techniques on the same day for each patient.
Then, the unavailability of the XL probe did not allow the assess-
ment of the liver elasticity in the cases of overweight patients.
Finally, the small number of patients who underwent a liver
biopsy was also a limitation in the absence of comparison to a
reference examination.

9. Conclusions

In our study performed in “real life situations”, it appears
clearly that the SWE is as powerful as the FS in order to evaluate
the hepatic elasticity. This new technique has the advantage of
being integrated in a conventional ultrasound system. It can be
performed during a standard liver ultrasound in B mode.

It could be an alternative for hepatology departments which are not equipped with a FS with an XL probe for the examination
of patients with a high BMI.

In the light of the results of this work, studies become there-
fore a necessity and will have to be dedicated to explore factors
that could influence the results of the SWE.

Acknowledgments

We would like to thank Mrs Fanny Hadad for reviewing the
English manuscript.

Author contributions

HT.Z: design of the study, collecting the data, writing of the
manuscript.

JFD.C: design of the study, writing of the manuscript, practicing
Fibroscan®.

G.F: care of patients, relecture of the manuscript.

B.A: design of the study, practicing Shear Wave, relecture of the
manuscript.

R.S: care of patients, relecture of the manuscript.

JR.NE: care of patients, relecture of the manuscript.

S.M: care of patients, relecture of the manuscript.

F.K: design of the study, practicing Shear Wave, relecture of the
manuscript.

T.LM: design of the study, data collection, statistical analysis.

References

[1] Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and
risk factors in a general population using non-invasive biomarkers
(FibroTest). BMC Gastroenterol. 2010;10:40.

[2] European Association for the Study of the Liver. EASL Clinical Practice
Guidelines: management of hepatitis C virus infection. J Hepatol.
2011;55:245–64.

[3] Cadranel J-F, Ruffat P, Degos F. Practices of liver biopsy in France: result
of a prospective nationwide survey. Hepatology. 2000;32:477–81.

[4] European Association for the Study of the Liver. EASL Clinical Practice
Guidelines on non-invasive tests for evaluation of liver disease severity
and prognosis. J Hepatol. 2021;73:639–89.
[5] Huet N, Denis I, Martino A, et al. Ultrasoundographic assessment of liver fibrosis with computer-assisted analysis of liver surface irregularities. Diag Interv Imaging. 2015;96:941–6.

[6] Muller M, Gennisson JL, Defoort T, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. Ultrasound Med Biol. 2009;35:219–29.

[7] Buvé E, Gennisson JL, Couade M, et al. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 patients. Ultrasound Med Biol. 2011;37:1361–73.

[8] Ferraoli G, Tinelli C, Dal BB, et al. Accuracy of real time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012;56:2125–33.

[9] Sandrin L, Fourquet B, Hasquesnon JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.

[10] Castéra L, Chan HLY, Arrese M. For the Clinical Practice Guideline Panel. EASL-CLIP clinical practice guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.

[11] Bamber J, Cosgrove D, Dietrich CF, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1. Basic principles and technology. Ultraschall Med. 2013;34:169–84.

[12] Cosgrove D, Piscaglia F, Bamber J, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2. Clinical applications. Ultraschall Med. 2013;34:238–53.

[13] Sporea I, Gradinaru-Tascau O, Boto S, et al. How many measurements are needed for liver stiffness assessment by 2D-Shear Wave Elastography (2D-SWE) and which value should be used: the mean or median? Med Ultrason. 2013;15:268–72.

[14] Pissart A, Lemone S, Cassinotto C, et al. Reliability criteria of two-dimensional shear wave elastography: analysis of 4277 measurements in 788 patients. Clin Gastroenterol Heperol. 2020;20:400–408.e10.

[15] Friedrich-Rust M, Onf MF, Martens S. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterol. 2008;134:960–74.

[16] R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.

[17] Van der Poorten D, Kwok A, Lam T, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J. 2006;36:692–9.

[18] Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C: A cost-effectiveness analysis. Ann Intern Med. 2000;133:665–75.

[19] Zioul M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in pa tients with chronic hepatitis C. Hepatology. 2005;41:48–54.

[20] Castéra L, Vergniol J, Foucher J, et al. Pro sceptive comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50.

[21] Lupors Platon M, Stefanescu H, Feier D, et al. Performance of unidimensional transient elastography in staging chronic hepatitis C: results from a cohort of 1,202 bi opsed patients from one single center. J Gas troenterol Liver Dis. 2015;22:137–66.

[22] Marcellin P, Zioul M, Redossa P, et al. Non invasive assessment of liver fibrosis by stiff ness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242–7.

[23] Castéra L, Bernard PH, Le Bail B, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharc mol Ther. 2011;33:455–65.

[24] Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic per formance of transient elastography in pa tients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32:612–21.

[25] Degos F, Perez F, Roche B, et al. Diagnos tic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic vi ral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013–21.

[26] Saito H, Tada S, Nakamoto N, et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res. 2004;29:97–103.

[27] Castéra L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–1302.e4.

[28] Oliveri F, Coco B, Ciccorossi P, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influ enced by the pattern of transaminases. World J Gastroenterol. 2008;14:6134–620.

[29] Toschatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta analysis of diagnostic accuracy. J Hepatol. 2011;54:650–9.

[30] Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Heperol. 2007;5:1214–20.

[31] Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of di agnostic test accuracy. Am J Gastroenterol. 2007;102:2589–600.

[32] Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-inva sive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokteratin-18 fragments. Aliment Pharmacol Ther. 2014;39:234–69.

[33] Puigvehl M, Broquetas T, Coll S, et al. Impact of anthropometric features on the applicability and accuracy of FibroScan® (M and XL) in overweight/obese patients. J Gastroenterol Hepatol. 2017;32:1746–53.

[34] Foucher J, Castéra L, Bernard PH, et al. Prevalence and factors asso ciated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Heperol. 2006;18:411–2.

[35] Hermann E, De Lédignen V, Cassinotto C, et al. Assessment of biopsy-proven liver fibrosis by 2D-shear wave elastography an individual patient data based meta-analysis. Hepatology. 2018;67:260–72.

[36] Karagiannakis DS, Theodoros V, Theodoros A, et al. Comparative utility of transient and 2D Shear Wave Elastography for the assessment of liver fibrosis in clinical practice. J Dig Imaging. 2021;34:1342–8.

[37] Leug YY, Shen J, Wong VW, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology. 2013;269:910–9.

[38] Zeng J, Liu GJ, Huang ZP, et al. diagnosis accuracy of twodimensional shear wave elastography for the noninvasive staging of hepatic fibrosis in chronic hepatitis B: a cohort study with internal validation. Eur Radiol. 2014;24:2572–81.

[39] Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gastro. 2007;36:968–73.

[40] De Lédignen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043–8.

[41] Olteanu VA, Balan GGH, Gilca-Blanariu G-E, et al. Biases of Shear Wave vs Transient Elastography in fibrosis assessment of patients with fatty liver disease. Rom Biotechnol Lett. 2020;25:1289–95.